Answers are grounded in this paper and cite their sources.
Introduction The aim of this retrospective study on biopsy-proven lupus nephritis (LN) patients is to assess the probability of sustained clinical remission (sCR) and to investigate sCR effects on disease flares and impaired kidney function (IKF). Methods sCR was defined as clinical-SLEDAI-2K=0 and eGFR>60ml/min/1.73m 2 lasting≥1 year; IKF: eGFR<60ml/min/1.73m 2 for>3 months. We analysed the probability of achieving and maintaining sCR, and the yearly risk of flare. Cox models were used to identify predictors of sCR and IKF with variables analysed as time-depending covariates when appropriate. Results Out of 303 patients followed for 14.8 (IQR 9.8-22) years, 257 (84.8%) achieved sCR. The probability of achieving sCR progressively increased over time reaching 90% at 15 years. Baseline age (HR: 1.017;95%CI:0.005-1.029; p=0.004), hydroxychloroquine intake (HR: 1.385;95%CI:1.051-1.825; p=0.021), and absence of arterial hypertension (HR: 0.699;95%CI:0.532-0.921; p=0.011) were independent predictors of sCR. Among patients who achieved sCR, 142 (55.3%) developed a lupus flare after a median time of 3.6 (2.3-5.9) years. In the remaining 115 patients, sCR persisted for 9.5 (5.8-14.5) years. The probability of sCR to persist at 15 years was 38%. SLE flare risk decreased to 10%, 5%, and 2% in patients with sCR lasting <5, 5-10, and >10 years, respectively. At last observation, 57 patients (18.81%) had IKF. sCR achievement (HR=0.18, p<0.001) and its duration (HR=0.83, p<0.001) were protective against IKF. Conclusion sCR is an achievable target in LN management and protects against IKF. The longer the sCR, the higher the chance of its persistence and the lower the risk of SLE flares.
No takes yet. Share an insight, caveat, or question.
Gatto et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: